FINWIRES · TerminalLIVE
FINWIRES

Leerink Partners Upgrades Innate Pharma to Outperform From Market Perform, Adjusts PT to $4 From $3

By

Innate Pharma (IPHA) has an average rating of buy and mean price target of $6.69, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles

Research

Wedbush Downgrades Sionna Therapeutics to Neutral From Outperform, Adjusts PT to $5 From $53

Wedbush Downgrades Sionna Therapeutics to Neutral From Outperform, Adjusts PT to $5 From $53

$SION
Research

Argus Upgrades Sandisk to Buy From Hold, Price Target is $1,600

Sandisk (SNDK) has an average rating of overweight and mean price target of $2,190.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$SNDK
Research

BNP Paribas Downgrades Coca-Cola HBC to Neutral, Lifts PT

BNP Paribas on Monday downgraded bottling company Coca-Cola HBC (CCH.L) to neutral from outperform and raised its price target to 50.00 pounds sterling from 47.00 pounds.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$CCH.L